

# NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

## HEALTH TECHNOLOGY APPRAISAL PROGRAMME

### Equality impact assessment – Guidance development

#### STA - Bortezomib for induction therapy in multiple myeloma before high dose chemotherapy and autologous stem cell transplantation

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme.

#### Consultation

1. Have the potential equality issues identified during the scoping process been addressed by the Committee, and, if so, how?

At the scoping consultation stage, one consultee highlighted that myeloma mostly affects the elderly population, who often have other concomitant conditions and so there may be an impact on the equality of access for these patients. This was not considered to be an issue of the equality legislation for an appraisal topic. No additional issues related to potential equality issues have been identified during the scoping process.

This issue was therefore not considered further by the Committee.

2. Have any other potential equality issues been raised in the submissions, expert statements or academic report, and, if so, how has the Committee addressed these?

No equality issues were highlighted in the evidence submitted for the appraisal.

3. Have any other potential equality issues been identified by the

Technology appraisals: Guidance development

Equality impact assessment for the single technology appraisal of bortezomib for induction therapy in multiple myeloma before high dose chemotherapy and autologous stem cell transplantation

1 of 4

Issue date: April 2014

Committee, and, if so, how has the Committee addressed these?
No.

4. Do the preliminary recommendations make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group?
No.

5. Is there potential for the preliminary recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?
No.

6. Are there any recommendations or explanations that the Committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 4 or 5, or otherwise fulfil NICE's obligations to promote equality?
Not applicable.

7. Have the Committee's considerations of equality issues been described in the appraisal consultation document, and, if so, where?
No equality issues relevant to the Committees preliminary recommendations were raised (see ACD summary table)

**Approved by Associate Director (name):** Frances Sutcliffe

**Date:** 31 10 2013

Technology appraisals: Guidance development  
Equality impact assessment for the single technology appraisal of bortezomib for induction therapy in multiple myeloma before high dose chemotherapy and autologous stem cell transplantation

## Final appraisal determination

(when an ACD issued)

1. Have any additional potential equality issues been raised during the consultation, and, if so, how has the Committee addressed these?

No.

2. If the recommendations have changed after consultation, are there any recommendations that make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group?

No.

3. If the recommendations have changed after consultation, is there potential for the recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?

No.

4. If the recommendations have changed after consultation, are there any recommendations or explanations that the Committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 2 and 3, or otherwise fulfil NICE's obligations to promote equality?

No.

5. Have the Committee's considerations of equality issues been described in the final appraisal determination, and, if so, where?

No, none identified.

**Approved by Centre or Programme Director (name):** Meindert Boysen

**Date:** 14 March 2014